- Home
- IGMS
IGMS
IGM Biosciences Inc.
as 11-15-2024 4:00pm EST
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 962.1M | IPO Year: | 2019 |
| Target Price: | $14.63 | AVG Volume (30 days): | 238.9K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.72 - $22.50 | Next Earning Date: | 11-08-2024 |
| Revenue: | $2,918,000 | Revenue Growth: | 57.64% |
| Revenue Growth (this year): | 298.54% | Revenue Growth (next year): | -22.50% |
Stock Insider Trading Activity of IGM Biosciences Inc. (IGMS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decker Lisa Lynn | IGMS | CHIEF BUSINESS OFFICER | Sep 13 '24 | Sell | $11.54 | 925 | $10,673.39 | 79,104 | |
| Schwarzer Fred | IGMS | CEO AND PRESIDENT | Sep 13 '24 | Sell | $11.54 | 3,946 | $45,532.10 | 250,124 | |
| Tahir Misbah | IGMS | CHIEF FINANCIAL OFFICER | Sep 13 '24 | Sell | $11.54 | 1,487 | $17,158.20 | 122,694 | |
| Harler Mary Beth | IGMS | Head, Research & Autoimmunity | Sep 13 '24 | Sell | $11.54 | 1,487 | $17,158.20 | 163,740 | |
| Keyt Bruce | IGMS | CHIEF SCIENTIFIC OFFICER | Sep 13 '24 | Sell | $11.54 | 1,487 | $17,158.20 | 242,948 | |
| Takimoto Chris H | IGMS | CHIEF MEDICAL OFFICER | Sep 13 '24 | Sell | $11.54 | 1,487 | $17,158.20 | 154,331 |
Latest IGM Biosciences Inc. News
IGMS Breaking Stock News: Dive into IGMS Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
9 days ago
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
9 days ago
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Simply Wall St.
10 days ago
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
13 days ago
IGM Biosciences to Present at Three Upcoming Investor Conferences
MT Newswires
a month ago
RBC Raises Price Target on IGM Biosciences to $20 From $17, Keeps Outperform, Speculative Risk
Barrons.com
2 months ago
These Stocks Moved the Most Today: APA, Northrop, Boeing, Super Micro, HP Inc., Tesla, Li Auto, CVS, Ford, and More
Investor's Business Daily
2 months ago
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
Compare IGMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IGMS IGM Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.